Corcept Therapeutics sets July 29 Q2 call as Lifyorli launch and relacorilant review take centre stage
Corcept Therapeutics will report Q2 results on July 29, with Lifyorli launch sales, Korlym growth and relacorilant’s FDA review in focus.
Pharma & Biotech